Trials / Unknown
UnknownNCT05964634
Effect of Peripapillary Atrophy to Diagnose Glaucoma in High Myopia
Effect of Peripapillary Atrophy Based on Optical Coherence Tomography to Diagnose Primary Open Angle Glaucoma in High Myopia
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study intends to analyze the characteristics between peripapillary retinal nerve fiber layer thickness and peripapillary area in high myopia with or without glaucoma
Detailed description
Glaucoma is the leading cause of irreversible blindness in the world. Myopia is a risk factor for glaucoma. With the rising prevalence of both myopia and glaucoma in an ageing population, the occurrence of these two ocular conditions in the same patient is likely to increase. It was estimated that there were 163 million people who have high myopia in 2000, and the population with high myopia would increase to almost one billion (9.8% of the world population) worldwide by 2050. There is often a diagnostic challenge to the clinician, since the detection of glaucomatous optic nerve damage in highly myopic eyes is difficult. Recently, the subclassification of peripapillary area could potentially be used to differentiate myopic eyes with and without glaucoma according to OCT findings. However, the characteristics of peripapillary atrophy have not been fully applied in the diagnosis of high myopia and glaucoma. In view of the above problems, the purpose of this study is to analyze the peripapillary area based on optical coherence tomography and it may be a specific marker for identifying high myopia with primary open angle glaucoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | OCT imaging | Image J or Spectralis OCT built-in software package was used to manually locate and measure the area and width of the temporal parapapillary atrophy. |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2024-11-30
- Completion
- 2025-01-31
- First posted
- 2023-07-28
- Last updated
- 2023-07-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05964634. Inclusion in this directory is not an endorsement.